BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which includes a workforce reduction of over 30%. The Company estimates that it will ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of n ...

The following is a summary of “Long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD,” ...

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated ...

Lipid abnormalities are a common complication in diabetic kidney disease (DKD), contributing to disease progression and ...

AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.

(1) A non-GAAP financial measure or ratio which does not have a standardized meaning under the "Accounting Standards", see "Non-GAAP Measures" section of this press release. (2) A supplementary ...